The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

CURNA, Inc. was engaged in manufacturing pharmaceutical products. The company was headquartered in Jupiter, FL.

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people's lives.

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical identification and treatment of evaporative dry eye. Of the 100 million plus of dry eye sufferers worldwide, the leading cause (86percent) is evaporative dry eye, which is caused by Meibomian Gland Dysfunction (MGD) and a lipid deficiency of the eye’s natural tear film. The Tear Film and Ocular Surface Society (TFOS) workshop, involving two years of work by 50 leading experts from around the world, concluded that MGD is an under-estimated condition and is very likely the most frequent cause of dry eye disease. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances. TearScience’s integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Szybio is engaged in the research and development, production, and sales of in vitro diagnostic reagents for clinical medicine. Their products and services include biochemical diagnostic reagent products, molecular diagnostic reagents, diagnostic testing-related equipment focusing on latex-enhanced immune turbidimetric technology products, and more.

Jiangsu Kanion Pharma is a pharmaceuticals company based out of LIANYUNGANG. Jiangsu Kanion Pharma representatives, don’t miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees.

Medtronic Vascular designs and develops technologies for coronary, peripheral, and neurovascular indications. The company’s products include S7 Zipper MX Coronary Stent System, Clo-Sur PAD Nonwoven Hydrophilic Wound Dressing, Launcher Coronary Guide Catheter, and Stormer Over-the-Wire Balloon Dilatation Catheter. The company also offers Bridge Assurant Balloon-Expandable Stent Delivery System, GuardWire Plus Temporary Occlusion and Aspiration System, and S660 Coronary Stent. Medtronic Vascular was incorporated in 1991 and is based in Santa Rosa, California. As of January 29, 1999, Medtronic Vascular operates as a subsidiary of Medtronic.

Morinaga & Co., Ltd. engages in the manufacture, purchase, and sale of confectioneries. It operates through the following business segments: Food Manufacturing, Food Merchandise and Restaurant, Real Estate and Services, and Others. The Food Manufacturing segment manufactures and distributes confectioneries, foodstuffs, frozen desserts, and health products. The Food Merchandise and Restaurant segment involves with the operation of restaurants. The Real Estate and Services segment deals with real estate business and operation of golf courses. The Others segment includes the manufacture and sale of research reagents. The company was founded by Taichiro Morinaga on August 15, 1899 and is headquartered in Tokyo, Japan.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.

Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA.

XOMA Technology Ltd., a subsidiary of XOMA Corp., is a company headquartered in Bermuda focused on pharmaceutical preparations.

Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.

Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany.

Changsha Feichuang Biotechnology Co., Ltd., established on 2018-03-15, Business scope includes biotechnology extension services;Biological product,Health products,Healthy food,medicine,special dietary food,Research and development of microbial technology application equipment;Call center service in the second type of value-added telecommunication service,Information service business(Internet information service only);Natural science research and experimental development;Materials Science Research,technology,Research on teaching equipment,Development of book data processing technology;Information Electronic Technology Services;translation service;Technology intermediary service;Science and Technology Information Consulting Services;Legal Document Agency Services;Chemical Reagents and Auxiliaries,Manufacture of Glass Instruments;Chemical reagents and daily chemical products(Free of hazardous and monitored chemicals)retail;Medical Laboratory Equipment and Appliances,Glassware Sales;Medical Research and Experimental Development;Conference Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Do not engage in unauthorizedP2Ponline loan,Equity crowdfunding,internet insurance,Asset management and cross-border finance,Third party payment,virtual currency transaction,ICO,Internet financial services such as illegal foreign exchange)

Zhenjiang Jintai Medical Laboratory Co., Ltd., established on 2012-09-05, The scope of business includes laboratory equipment,Instrumentation,Chemical Products(Hazardous chemicals and flammable and explosive materials are excluded),Sales of Class Ι Medical Devices;Health Information Consultation,medical test,Research and development of new biological products,Production,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)